FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
Lotimatou avorago bare									
hours per response:									
p soponoo.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							(, -			,									
1. Name and Address of Reporting Person* Goddard Glenn					<u>AC</u>	2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [AGIO]									all app	olicable) ctor	ig Perso	Person(s) to Issuer		
(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 05/27/2015								X	Officer (give title below) Senior Vice Presi		esident,	Other (specify below) ident, Finance		
88 SIDNEY STREET, 2ND FLOOR					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applic Line)					
(Street) CAMBRIDGE MA 02139					-										Form	Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(Si	tate) ((Zip)																	
		Tab	le I -	Non-Deri	vative	Se	curit	ties A	cquired	l, D	isposed	of, or E	Benefic	cially	Own	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yes				Year)	2A. D Execu if any (Mon	ition					ties Acqui I Of (D) (In	4 and 5) Secu Bend Own		ficially d	6. Ownership Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price				(Instr. 4)		(Instr. 4)		
Common stock 05/27/2015					15	5			M ⁽¹⁾		2,171	A	\$2	3.1		2,171	D			
Common stock 05/27/2015			15	.5		S ⁽²⁾		2,171	D	\$120	0.05(3)		0	D						
		Ta	able	II - Deriva (e.g., p							posed of convert				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code 8)		Of Der Sec (A) Dis of (posed	6. Date Exerci Expiration Da (Month/Day/Yo		ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Sec (Ins	vative irity	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	n: ct (D) idirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amour or Number of Shares	er						
Stock option (right to buy)	\$23.1	05/27/2015			M ⁽¹⁾			2,171	(4)		08/27/2023	Common stock	2,17	l \$(0.00	109,098		D		

Explanation of Responses:

- $1. \ This \ exercise \ was \ effected \ pursuant \ to \ a \ Rule \ 10b5-1 \ trading \ plan \ adopted \ by \ the \ reporting \ person.$
- 2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 3. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$120.00 to \$120.81. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 4. This option was granted on August 28, 2013. The shares underlying this option vest as to 25% of the underlying shares on August 28, 2014, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Remarks:

<u>/s/ Glenn Goddard</u> <u>05/28/2015</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.